Dr. Christian Dubiella
Job title:
Areas of work:
- mRNA delivery and formulation
- Lipid nanoparticle (LNP) technology
- Nucleic acid (RNA/DNA) delivery systems
- Drug development (pre-clinical and clinical)
- Cell and gene therapy techniques
- Nanoparticle-based pharmaceutical formulations
- Leadership in pharmaceutical research and project management
- Vaccine and advanced therapy development
Presentation at TTC – Process Analytical Conference 2026
Title: mRNA LNP Manufacturing Essentials: DSP and Analytical Considerations
Detailed Bio
Dr. Christian Dubiella is an mRNA delivery and lipid nanoparticle (LNP) formulation expert, currently serving as Technology Manager and Senior Group Leader at Wacker in Munich, Germany. He holds a PhD (Dr. rer. nat.) in Biochemistry from the Technical University of Munich, where he specialized in the development and characterization of selective immunoproteasome inhibitors.
Dr. Dubiella’s career spans over 12 years in pre-clinical and clinical drug development across academic and industrial settings, with more than five years dedicated to nanoparticle-based formulations and RNA/DNA delivery. He has held key roles in nucleic acid research and product development at Wacker, worked as Head of Nucleic Acid Delivery at leon-nanodrugs. His research at the Weizmann Institute of Science and Technical University of Munich led to several patented innovations and first-author publications in leading journals.
He has contributed to projects such as Germany’s Pandemic Preparedness Program and holds four pharmaceutical invention patents. Dr. Dubiella is recognized for advancing new therapies and vaccines, focusing on cell and gene therapy, mRNA-based therapeutics, and innovative delivery platforms.